CDK4/6抑制剂治疗乳腺癌的预后指标：预后营养指数。
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index.
作者信息
Keskinkilic Merve, Semiz Huseyin Salih, Polat Gul, Arayici Mehmet Emin, Yavuzsen Tugba, Oztop Ilhan
机构信息
Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, 35330, Turkey.
Department of Medical Oncology, Dokuz Eylul University, Institute of Oncology, Izmir, 35330, Turkey.
出版信息
Future Oncol. 2023 Apr 26. doi: 10.2217/fon-2022-1023.
The aim of this study was to evaluate the effect of prognostic nutritional index (PNI) on prognosis in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received CDK4/6 inhibitor + endocrine therapy. Patients receiving a CDK4/6 inhibitor were evaluated retrospectively. The PNI was calculated as: (10 × serum albumin [g/dl]) + (total lymphocyte count [×10/l] × 5). In a study of 106 patients, a statistically significant survival advantage was observed in the high-PNI group over the low-PNI group (mean overall survival: 28.03 ± 0.487 months vs 22.46 ± 1.14 months; p = 0.013). For the first time in the literature, this study demonstrated the prognostic role of PNI in patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors.
本研究的目的是评估预后营养指数（PNI）对接受CDK4/6抑制剂+内分泌治疗的激素受体阳性、HER2阴性转移性乳腺癌患者预后的影响。对接受CDK4/6抑制剂治疗的患者进行回顾性评估。PNI的计算方法为：（10×血清白蛋白[g/dl]）+（淋巴细胞总数[×10⁹/l]×5）。在一项针对106例患者的研究中，高PNI组比低PNI组观察到具有统计学意义的生存优势（平均总生存期：28.03±0.487个月 vs 22.46±1.14个月；p=0.013）。本研究首次在文献中证明了PNI在接受CDK4/6抑制剂治疗的激素受体阳性、HER2阴性转移性乳腺癌患者中的预后作用。
Zotero 插件